Global Health Innovative Technology Fund

Last updated

The Global Health Innovative Technology Fund (GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), 16 pharmaceutical and diagnostics companies (Astellas, Chugai, Eisai, Daiichi Sankyo, Fujifilm, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck Group, Mitsubishi Tanabe, Nipro, Otsuka, Shionogi, Sumitomo Dainippon, Sysmex and Takeda), the Bill & Melinda Gates Foundation, the Wellcome Trust and United Nations Development Programme. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. [1] [2] Bill Gates has noted that "GHIT draws on the immense innovation capacity of Japan’s pharmaceutical companies, universities and research institutions to accelerate the creation of new vaccines, drugs and diagnostic tools for global health." [3] Margaret Chan, former Director-General of the World Health Organization, said: "The GHIT Fund has stepped in to provide that incentive in a pioneering model of partnership that brings Japanese innovation, investment and leadership to the global fight against infectious disease." [4]

Contents

The GHIT Fund is the first public-private partnership fund to involve a national government, a UN agency, a consortium of pharmaceutical and diagnostics companies, and international philanthropic foundations. [5] [6]

The public-private partnership model, the inclusion of a whole pharmaceutical sector and the structure of individual research projects across sectors and national boundaries are all aimed at reducing the R&D risk to any one entity and to ensure that findings are open to all. [6] Another key opportunity the GHIT Fund has created has been to help open the doors of Japan’s public and private drug compound libraries to product development partnerships, which makes possible the screening of tens of thousands of drug candidates for potential new treatments. [7]

The participating companies view their investments into neglected diseases through the Fund as a long-term investment into the future, rather than charity. They see the Fund as a necessary catalyst for having allowed them to pursue this line of research. [8]

By 2022 (the end of the Fund’s second five-year phase), GHIT aims to bring two of its projects to a stage where a request for regulatory approval is filed. One of the products in the pipeline and among the closest to hitting the market is a pediatric formulation of praziquantel, a drug widely used to schistosomiasis, a disease caused by parasitic flatworms. [9]

Conceptualization and establishment

The idea of a Japanese nonprofit focused on global health R&D was conceived during a conversation between Tachi Yamada and former executive at Eisai Co. Ltd., BT Slingsby – the fund's first CEO and founder of GHIT. [10] [11] A launch committee was set up in 2012 among the Government of Japan's Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare, Astellas, Daiichi Sankyo, Eisai, Shionogi, Takeda, the Bill & Melinda Gates Foundation. This committee worked collectively to design the organization based on the idea that new investment and innovation are needed to address some of the world’s most neglected diseases [12] and that Japan – a leader in health technologies innovation – could be doing more in the global fight against infectious diseases. [13] The launch committee also designed the unique governance model to minimize potential conflicts of interest in investment decision making. [14] In 2013, the GHIT Fund formally launched with an initial commitment of over US$100 million. [5] Original Board members included Kiyoshi Kurokawa, Peter Piot, Ann Veneman, and Ko-Yung Tung. [15]

Vision and mission

In their own words, the vision of the founders of the GHIT Fund is “one in which the crushing burden of infectious disease no longer prevents billions of people in the developing world from seeking the level of prosperity and longevity now common in the industrialized world”. [16]

The Fund’s stated mission is to “to facilitate international partnerships that enable Japanese technology, innovations, and insights to play a more direct role in reducing disparities in health between the rich and the poor of the world.” [16]

In keeping with this vision and mission, global health R&D is considered to be a indispensable to the realization of universal health coverage (UHC), for which Japan is a major proponent. [17]

Investment approach

The GHIT Fund invests across four research platforms (Target Research, Screening, Hit-to-Lead, and Product Development) in R&D partnerships among Japanese pharmaceutical companies and research institutes and universities with non-Japanese research institutes and universities. [18] This gives researchers around the world access to Japanese expertise and investment. [19] The Fund deliberately refers to grants as "investments" and grantees as "development partners." [20]

Investments go to R&D projects that aim to develop new health technologies for infectious diseases. Diseases targeted by the Fund include HIV, malaria, tuberculosis, and neglected tropical diseases. [1] The Fund also works with established product development partnerships such as the Global Alliance for Tuberculosis Drug Development (TB Alliance), Medicines for Malaria Venture, and Geneva-based Drugs for Neglected Diseases initiative to screen the large quantity of potential drug candidates residing in private and public sector chemical compound libraries in Japan. [21]

The GHIT Fund utilizes private-sector standards for product development (e.g., using typical milestones and stage-gates for timeline management). GHIT invests heavily in management and evaluation of projects and is rigorous about achievement milestones, swiftly terminating non-performers. But while GHIT has a “private-sector” orientation to the management of investments, there is no expectation of financial return. [20]

Co-funding of projects is another key investment management tool. Candidate products that have achieved proof-of-concept (POC) are required to have a co-funding strategy in place, though GHIT strongly encourages co-funding for the entire portfolio. In December 2017 GHIT announced a partnership with the European & Developing Countries Clinical Trials Partnership (EDCTP) [22] to support product development research, specifically by co-funding the PZQ4PSAC phase III clinical study, which is sponsored by Merck KGaA and conducted by the Pediatric Praziquantel Consortium. [23] This study provides clinical data and support for registration of a new praziquantel (PZQ) tablet formulation to treat schistosomiasis in preschool-aged children. The GHIT Fund's full investment portfolio, with detailed background on specific development partnerships, is on its website. [24]

Funding for GHIT

In 2013, the original partners to the Fund initially committed over US$100 million over 5 years. Half came from the two Japanese ministries, and the other half came from Japanese pharma Astellas, Eisai, Daiichi Sankyo, Shionogi, and Takeda together with the Bill & Melinda Gates Foundation. [1] [19] [25]

By 2015, funding for GHIT increased to US$140 million with the addition of new partners and sponsors. New partners Chugai, Sysmex, and the Wellcome Trust had joined. The Wellcome Trust alone brought in an additional approximately US$4.6 million through January 2017. [2] Three additional companies (All Nippon Airways, law firm Morrison Foerster LLP, and Yahoo!Japan) joined the Fund as sponsors in the summer of 2015 to provide in-kind services in support of the Fund’s work. Yahoo!Japan has co-launched a special joint website with the Fund: “Save millions of lives from infectious diseases” Archived 9 October 2015 at the Wayback Machine . [2]

A replenishment for the GHIT's second five-year phase was initiated in May 2016 as the Government of Japan announced as part of a G7 Summit communique a US$130 million contribution to the GHIT Fund/UNDP. [26] On June 1, 2017 GHIT announced it had secured commitments of over US$200 million for its next phase of work, allowing it to move the most advanced tools out of the lab, and into the hands of those who need them most. [27] The new commitment for GHIT’s second phase is double the initial US$100 million investment GHIT received when it was created in 2013. Also in June 2016 ten companies joined GHIT, including a full funding partnership with FUJIFILM Corporation, an associate partnership with Otsuka Pharmaceutical, affiliate partnerships with GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe Pharma Corporation, Nipro Corporation, Sumitomo Dainippon Pharma, and a sponsorship from Salesforce.com. [28]

There are currently three levels of pharmaceutical and diagnostic partners - Full partners, Associate partners, and Affiliate partners. Additionally, non-biopharmaceutical companies engage as Sponsors, contributing in-kind services to reduce the overhead expenses of the Fund. [29]

Impact

GHIT’s Phase 2.0 strategic plan anticipates that by the end of FY2022 two products in its pipeline will be approved by a stringent regulatory authority. As of December 2017 GHIT has invested over of US$115 million across four research platforms into more than 60 global product development partnerships that leverage Japanese innovation and capacities in pharmaceuticals. [30] Seven of the 24 novel screening programs have advanced into next stage of development; six candidates have successfully achieved first-in-human trials, and two projects have achieved Proof of Concept (Phase II). [31] Approximately 42% of GHIT’s investments have been allocated to projects related to malaria, 13% to tuberculosis, and the rest to NTDs. With regard to product type, 71% of investments have been in drugs, 24% in vaccines, and the rest in diagnostics. [32]

Products resulting from research must be appropriate, effective, affordable, and accessible for the poorest of the poor. [5] In fact, all grant investment proposals must prioritize open innovation [33] and guarantee that products will be developed on a "no gain, no loss" basis, [1] meaning in the poorest countries drugs will be licensed without royalties, while in others, they will be licensed at cost. [34]

Leadership & Governance

GHIT is governed and managed by an international Board of Directors. The Board is responsible for establishing the organization’s by-laws, providing fiduciary oversight, approving investment recommendations from the Selection Committee, and assessing the Fund’s overall performance. Dr. Kiyoshi Kurokawa [35] is Chair of the Board and Dr. BT Slingsby is the founding CEO and Executive Director. [36]

GHIT’s Selection Committee operates separately from the Board of Directors. This is to ensure objectivity, transparency, and accountability of the investment-making and evaluation process. The Selection Committee consists of renowned experts in product development for infectious diseases from across the globe and evaluates proposals, development partner reports, and recommends the provision of GHIT’s investments to the Board. [37] To add another layer of accountability and scientific rigor, External Reviewers consisting of more than 100 global health experts from around the world provide independent reviews of R&D proposals to the GHIT Fund and its Selection Committee. To further preemptively counter any potential conflicts of interest, all Selection Committee members, including academicians, must declare that they have no relation to proposal applicants or abstain from any decision-making process in the instance when they may.

GHIT’s Council, which includes participating pharmaceutical companies and government and international funding entities, provides oversight for the Board of Directors and advocates for GHIT’s mission. Council members are never involved in operational and/or funding decisions. [38]

Related Research Articles

<span class="mw-page-title-main">Wellcome Trust</span> British healthcare research charity established in 1936

The Wellcome Trust is a charitable foundation focused on health research based in London, in the United Kingdom. It was established in 1936 with legacies from the pharmaceutical magnate Henry Wellcome to fund research to improve human and animal health. The aim of the Trust is to "support science to solve the urgent health challenges facing everyone." It had a financial endowment of £Financial Times as the United Kingdom's largest provider of non-governmental funding for scientific research, and one of the largest providers in the world. According to their annual report, the Wellcome Trust spent GBP £1.1Bn on charitable activities across their 2019/2020 financial year. According to the OECD, the Wellcome Trust's financing for 2019 development increased by 22% to US$327 million.

<span class="mw-page-title-main">Eisai (company)</span> Japanese pharmaceutical company

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

TB Alliance is a not-for-profit product development partnership (PDP) dedicated to the discovery and development of new, faster-acting and affordable tuberculosis (TB) medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history. It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Neglected tropical diseases</span> Diverse group of tropical infectious diseases which are common in developing countries

Neglected tropical diseases (NTDs) are a diverse group of tropical infections that are common in low-income populations in developing regions of Africa, Asia, and the Americas. They are caused by a variety of pathogens, such as viruses, bacteria, protozoa, and parasitic worms (helminths). These diseases are contrasted with the "big three" infectious diseases, which generally receive greater treatment and research funding. In sub-Saharan Africa, the effect of neglected tropical diseases as a group is comparable to that of malaria and tuberculosis. NTD co-infection can also make HIV/AIDS and tuberculosis more deadly.

The Grand Challenges in Global Health (GCGH) is a research initiative launched by the Bill & Melinda Gates Foundation in search of solutions to health problems in the developing world. Fifteen challenges are categorized in groups among seven stated goals plus an eighth group for family health. The disciplines involved include immunology, microbiology, genetics, molecular biology and cellular biology, entomology, agricultural sciences, clinical sciences, epidemiology, population and behavioral sciences, ecology, and evolutionary biology.

<span class="mw-page-title-main">National Organization for Rare Disorders</span> U.S. nonprofit organization

The National Organization for Rare Disorders (NORD) is an American non-profit organization aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.

Medicines for Malaria Venture (MMV), a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999. Its mission is to reduce the burden of malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs. Its vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate the disease.

The Health Impact Fund is a proposed pay-for-performance mechanism that would provide a market-based solution to problems concerning the development and distribution of medicines globally. It would incentivize the research and development of new pharmaceutical products that make substantial reductions in the global burden of disease. The Health Impact Fund is the creation of a team of researchers led by the Yale philosopher Thomas Pogge and the University of Calgary economist Aidan Hollis, and is promoted by the non-profit organization Incentives for Global Health (IGH).

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

Some authors advocating patent reform have proposed the use of prizes as an alternative to patents. Critics of the current patent system, such as Joseph E. Stiglitz, say that patents fail to provide incentives for innovations which are not commercially marketable. Stiglitz provides the idea of prizes instead of patents to be awarded in order to further advance solutions to global problems such as AIDS.

<span class="mw-page-title-main">LifeArc</span>

LifeArc is a British life science medical research charity. It was established in 2000 as MRC Technology to translate the work of UK Medical Research Council (MRC) research scientists.

The London Declaration on Neglected Tropical Diseases was a collaborative disease eradication programme launched on 30 January 2012 in London. It was inspired by the World Health Organization roadmap to eradicate or prevent transmission for neglected tropical diseases by the year 2020. Officials from WHO, the World Bank, the Bill & Melinda Gates Foundation, the world's 13 leading pharmaceutical companies, and government representatives from US, UK, United Arab Emirates, Bangladesh, Brazil, Mozambique and Tanzania participated in a joint meeting at the Royal College of Physicians to launch this project. The meeting was spearheaded by Margaret Chan, Director-General of WHO, and Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Alliance for Biosecurity</span>

The Alliance for Biosecurity is a consortium of companies that develop products to respond to national security threats, including bioterrorism pathogens and emerging infectious diseases. It is headquartered in Washington DC.

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global nonprofit partnership focused on supporting the development of new antibacterial products. Its mission is to strengthen the pipeline of vaccines, rapid diagnostics, antibiotics and non-traditional products to prevent, diagnose and treat life-threatening bacterial infections.

Francisca Mutapi is a Professor in Global Health Infection and Immunity, co-Director of the Global Health Academy at the University of Edinburgh, and Deputy Director of the National Institute for Health Research (NIHR) Global Health Research Unit Tackling Infections to Benefit Africa. She is the first black woman known to have been awarded a professorship by the University of Edinburgh.

The Kigali Declaration on Neglected Tropical Diseases is a global health project that aims to mobilise political and financial resources for the control and eradication of infectious diseases, the so-called neglected tropical diseases due to different parasitic infections. Launched by the Uniting to Combat Neglected Tropical Diseases on 27 January 2022, it was the culmination and join commitment declared at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) hosted by the Government of Rwanda at its capital city Kigali on 23 June 2022.

References

  1. 1 2 3 4 “Japan in pioneering partnership to fund global health research”, by Andrew Jack, Financial Times, May 30, 2013
  2. 1 2 3 Fund), Global Health Innovative Technology Fund (GHIT. "Japanese Global Health Fund Welcomes the Wellcome Trust and Sysmex Corporation as New Funders and ANA, Morrison & Foerster, and Yahoo! Japan as New Sponsors". www.prnewswire.com (Press release). Retrieved 17 May 2023.
  3. ↑ "2030 CREATING FUTURE: Japan can lead the world in ending infectious diseases," May 9, 2016, The Asahi Shimbun, <http://www.asahi.com/ajw/articles/AJ201605090001.html>
  4. ↑ See WHO's video featuring Margeret Chan, WHO Director-General, here: https://ghitfund.org/general/eventreport2015 Archived 2019-11-01 at the Wayback Machine
  5. 1 2 3 Slingsby, BT; Kurokawa, Kiyoshi (2013). "The Global Health Innovative Technology (GHIT) Fund: Financing medical innovations for neglected populations". The Lancet Global Health. 1 (4): e184–5. doi: 10.1016/S2214-109X(13)70055-X . PMID   25104343.
  6. 1 2 "Medidata BrandVoice: Investing In Drugs That Won't Make Money". Forbes. Retrieved 17 May 2023.
  7. ↑ "The Value of Product Development Partnerships". The National Bureau of Asian Research (NBR). Retrieved 17 May 2023.
  8. ↑ Thomas, Ben (10 May 2013). "Article expired". The Japan Times. Retrieved 17 May 2023.
  9. ↑ Otake, Tomoko (12 December 2017). "Tokyo-based fund CEO leads public-private fight against diseases around globe". The Japan Times. Retrieved 17 May 2023.
  10. ↑ "Japan-based fund unites public, private sectors to fight infectious disease". Japan Today. Retrieved 17 February 2017.
  11. ↑ Daniel Poppy, “GHIT Fund Marks Japanese Government Interest In Exporting Tech for Global Health”, Pharm Asia, July 11, 2013, <https://scrip.pharmamedtechbi.com/SC084839/GHIT-Fund-Marks-Japanese-Government-Interest-In-Exporting-Tech-for-Global-Health>
  12. ↑ “Japan and Partners Team Up to Tackle Neglected Diseases”, by Dina Fine Maron, Scientific American, November 8, 2013 (http://www.scientificamerican.com/article.cfm?id=japan-and-partners-team) [ verification needed ]
  13. ↑ “Joining the Fight Against Neglected Diseases”, Science magazine, June 7, 2013, Volume 340, p.1148 [ verification needed ]
  14. ↑ Otake, Tomoko (12 December 2017). "Tokyo-based fund CEO leads public-private fight against diseases around globe". The Japan Times Online. ISSN   0447-5763 . Retrieved 1 January 2018.
  15. ↑ "GHIT Fund | Global Health Innovative Technology Fund". GHIT Fund(Global Health Innovative Technology Fund) (in Japanese). Retrieved 17 February 2017.
  16. 1 2 GHIT Fund website: About the GHIT Fund (www.ghitfund.org/about/organization/mission), accessed on 09/30/2014
  17. ↑ "Aiming for truly universal health coverage". 8 December 2017.
  18. ↑ “Give and It Shall Be Given unto You”, The Economist, November 16–22, 2013, p.72
  19. 1 2 Yamada, T (2013). "Tachi Yamada". Nature Reviews Drug Discovery. 12 (9): 658–9. doi:10.1038/nrd4110. PMID   23989787. S2CID   2654055.
  20. 1 2 Slingsby, Camilla Burkot, BT (7 December 2015). "Investing in innovation for health: an interview with BT Slingsby". Devpolicy Blog from the Development Policy Centre. Retrieved 17 May 2023.{{cite web}}: CS1 maint: multiple names: authors list (link)
  21. ↑ "Joining the Fight Against Neglected Diseases" in "Around the World". Science. 340 (6137): 1148–9. 2013. doi:10.1126/science.340.6137.1148-b.
  22. ↑ "EDCTP and Global Health Innovative Technology Fund partnership". EDCTP.
  23. ↑ "Pediatric Praziquantel Consortium - Pediatric Praziquantel Consortium". www.pediatricpraziquantelconsortium.org.
  24. ↑ "The GHIT Fund Portfolio | Global Health Innovative Technology Fund". Archived from the original on 1 February 2018. Retrieved 9 December 2014.
  25. ↑ "Japanese drugmakers get serious about tackling dengue". Nikkei Asia. Retrieved 17 May 2023.
  26. ↑ "Japan To Contribute US$130 Million Replenishment To GHIT Fund". Asian Scientist Magazine. 23 May 2016. Retrieved 17 May 2023.
  27. ↑ "FirstWord". firstwordpharma.com. Retrieved 17 May 2023.
  28. ↑ "GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma And Salesforce.com," The Street, June 5, 2016 <https://www.thestreet.com/story/13596511/3/ghit-fund-welcomes-ten-new-partnerships-with-fujifilm-otsuka-gsk-johnson-johnson-kyowa-hakko-kirin-merck-mitsubishi-tanabe-nipro-sumitomo-dainippon-pharma-and-salesforcecom.html Archived 2016-09-18 at the Wayback Machine >
  29. ↑ "GHIT Fund | Global Health Innovative Technology Fund". GHIT Fund(Global Health Innovative Technology Fund) (in Japanese). Retrieved 17 February 2017.
  30. ↑ "プレスリリース - 公益社団法人グローバルヘルス技術振興基金". www.ghitfund.org. Archived from the original on 1 November 2019. Retrieved 31 January 2018.
  31. ↑ Phillips, Margaret A; Lotharius, Julie; Marsh, Kennan; White, John; Dayan, Anthony; White, Karen L; Njoroge, Jacqueline W; El Mazouni, Farah; Lao, Yanbin; Kokkonda, Sreekanth; Tomchick, Diana R; Deng, Xiaoyi; Laird, Trevor; Bhatia, Sangeeta N; March, Sandra; Ng, Caroline L; Fidock, David A; Wittlin, Sergio; Lafuente-Monasterio, Maria; Benito, Francisco Javier Gamo; Alonso, Laura Maria Sanz; Martinez, Maria Santos; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Iñigo; Haselden, John N; Louttit, James; Cui, Yi; Sridhar, Arun; et al. (2015). "A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria". Science Translational Medicine. 7 (296): 296ra111. doi:10.1126/scitranslmed.aaa6645. PMC   4539048 . PMID   26180101.
  32. ↑ Otake, Tomoko (12 December 2017). "Tokyo-based fund CEO leads public-private fight against diseases around globe" – via Japan Times Online.
  33. ↑ Open innovation
  34. ↑ “Give and It Shall Be Given unto You”, The Economist, November 16–22, 2013, p.72
  35. ↑ "黒川清", Wikipedia (in Japanese), 16 March 2023, retrieved 17 May 2023
  36. ↑ "GHIT Fund | Global Health Innovative Technology Fund".
  37. ↑ "GHIT Fund - Global Health Innovative Technology Fund". GHIT Fund(Global Health Innovative Technology Fund).
  38. ↑ "GHIT Fund | Global Health Innovative Technology Fund". Archived from the original on 26 August 2018. Retrieved 20 October 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.